BACKGROUND: Activity of tamoxifen as a salvage therapy in patients with advanced epithelial ovarian cancer was evaluated by a number of studies. In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma. PATIENTS AND METHODS: A retrospective analysis was conducted of patients who received tamoxifen at a dose 20 mg twice daily for the treatment of advanced epithelial ovarian cancer. RESULTS: Twenty-nine eligible patients were included to the study. There were 1 (3%) complete response, 2 (7%) partial response, 6 (21%) stable disease, and 20 (69%) progressive disease. All patients were progressed after initiation of tamoxifen. Median progression-free survival was 4 mo (95% CI: 2.98-5.02). Disease progression of 19 (65%) patients were shown within the first 6 mo after initiation of tamoxifen. Progression-free survival was between 6 and 12 mo for 7 (24%) patients and > or =12 mo for 3 (10%) patients. The median survival after initiation of tamoxifen was 15 mo (95% CI: 7.2-22.8). No toxicity attributable to tamoxifen was seen in any of the patients. The only independent prognostic factor that had a significant predictive value for progression- free survival was the response to tamoxifen treatment (p = 0.043, hazard ratio: 0.12, 95% CI: 0.01-0.94). CONCLUSION: Considering minimal side effects and ability to cause objective responses, there is a place for tamoxifen in treatment of patients with platinum-resistant ovarian cancer. A phase III trial is required to con- firm the value of the drug in patients presenting these clinical settings.
BACKGROUND: Activity of tamoxifen as a salvage therapy in patients with advanced epithelial ovarian cancer was evaluated by a number of studies. In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma. PATIENTS AND METHODS: A retrospective analysis was conducted of patients who received tamoxifen at a dose 20 mg twice daily for the treatment of advanced epithelial ovarian cancer. RESULTS: Twenty-nine eligible patients were included to the study. There were 1 (3%) complete response, 2 (7%) partial response, 6 (21%) stable disease, and 20 (69%) progressive disease. All patients were progressed after initiation of tamoxifen. Median progression-free survival was 4 mo (95% CI: 2.98-5.02). Disease progression of 19 (65%) patients were shown within the first 6 mo after initiation of tamoxifen. Progression-free survival was between 6 and 12 mo for 7 (24%) patients and > or =12 mo for 3 (10%) patients. The median survival after initiation of tamoxifen was 15 mo (95% CI: 7.2-22.8). No toxicity attributable to tamoxifen was seen in any of the patients. The only independent prognostic factor that had a significant predictive value for progression- free survival was the response to tamoxifen treatment (p = 0.043, hazard ratio: 0.12, 95% CI: 0.01-0.94). CONCLUSION: Considering minimal side effects and ability to cause objective responses, there is a place for tamoxifen in treatment of patients with platinum-resistant ovarian cancer. A phase III trial is required to con- firm the value of the drug in patients presenting these clinical settings.
Authors: W Jager; W Sauerbrei; E Beck; V Maassen; M Stumpfe; W Meier; W Kuhn; F Janicke Journal: Anticancer Res Date: 1995 Nov-Dec Impact factor: 2.480
Authors: J D Ahlgren; N M Ellison; R J Gottlieb; F Laluna; J J Lokich; P R Sinclair; W Ueno; G L Wampler; K Y Yeung; D Alt Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544
Authors: Danielle Vicus; Barry Rosen; Jan Lubinski; Susan Domchek; Noah D Kauff; Henry T Lynch; Claudine Isaacs; Nadine Tung; Ping Sun; Steven A Narod Journal: Gynecol Oncol Date: 2009-07-03 Impact factor: 5.482
Authors: Harriet O Smith; Hugo Arias-Pulido; Dennis Y Kuo; Tamara Howard; Clifford R Qualls; Sang-Joon Lee; Claire F Verschraegen; Helen J Hathaway; Nancy E Joste; Eric R Prossnitz Journal: Gynecol Oncol Date: 2009-06-06 Impact factor: 5.482
Authors: Elizabeth Lokich; Rakesh K Singh; Alex Han; Nicole Romano; Naohiro Yano; Kyukwang Kim; Richard G Moore Journal: Sci Rep Date: 2014-06-30 Impact factor: 4.379
Authors: Maryam Burney; Lata Mathew; Anjali Gaikwad; Elizabeth K Nugent; Anneliese O Gonzalez; Judith A Smith Journal: Integr Cancer Ther Date: 2017-11-20 Impact factor: 3.279